Biocon

Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating leverage and a favourable product mix

Q1FY27 company results: Firms including JK Lakshmi Cement, Power Grid Corporation of India, Berger Paints, and Bikaji Foods are also to release their April-June earnings today

: Biocon Ltd on Wednesday said it has received notice of compliance approval from Canadian health regulator for its Yesintek (ustekinumab) autoinjector, indicated for the treatment of moderate to severe plaque psoriasis. The company's subsidiary in Canada has received Notice of Compliance (NOC) approval for Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL from Health Canada, Biocon Ltd said in a regulatory filing. Health Canada previously granted NOC for Yesintek (solution for subcutaneous injection) 45 mg/0.5ml (prefilled syringe and vial) and 90 mg/ml (prefilled syringe) and Yesintek I.V. (solution for intravenous infusion) 130 mg/26 mL (5mg/mL) in October 2025, it added. The availability of the Yesintek autoinjector provides patients with an option that the originator product does not offer in Canada, the company said . The new format will allow customised treatment approaches across care settings and patient needs, it added. Biocon said Yesintek is indicated for

Biocon shares climbed 6.5 per cent after reports of Viatris unit Mylan's planned stake sale, with analysts saying the move is a financial decision that removes a long-standing overhang

Mylan, part of global healthcare company Viatris, plans to sell up to 92 million shares in Biocon through a secondary offering valued at as much as Rs 34.81 billion

The team put together by the firm's founder may be just what the next decade demands

Chandan Taparia of Motilal Oswal decodes how to trade Nifty and Bank Nifty today; here are stock bets and strategy

Kiran Mazumdar-Shaw explained why she has chosen her niece, Claire, as her successor, outlining a five-year transition plan that will eventually see Claire take over as chairperson

Biocon is scouting for biosimilar in-licensing opportunities while banking on multiple FY27 product launches to drive growth, margins, and market expansion

Bengaluru-based Biocon said that its Q4 profit stood at ₹198.6. The profit was hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.

Biocon Ltd has reported a 56.8 per cent decline in consolidated net profit at Rs 198.6 crore in the fourth quarter ended March 31, hit by exceptional item outgo of Rs 80.4 crore on various heads, including impact of new labour code. The company had posted a consolidated net profit of Rs 459.4 crore in the corresponding period previous fiscal, Biocon Ltd said in a regulatory filing on Thursday. Consolidated revenue from operations in the fourth quarter was at Rs 4,516.6 crore as against Rs 4,417 crore in the year-ago period, it added. Total expenses in the fourth quarter were higher at Rs 4,241.2 crore as compared to Rs 3,987.5 crore in the same period a year ago, it said. The company's board has recommended a final dividend of 50 paise per equity share of face value of Rs 5 each for the financial year ended March 31, 2026, subject to shareholders' approval at the ensuing annual general meeting, Biocon said. For FY26, consolidated net profit was at Rs 368.8 crore, down from Rs 1,4

Q4FY26 company results: Firms including Lupin, Pidilite Industries, Bharat Forge, Escorts Kubota, and Indraprastha Gas are also to release their January-March earnings today

Biocon founder Kiran Mazumdar-Shaw outlines a five-year transition plan, naming niece Claire Mazumdar as successor to lead the company's next growth phase

Claire Mazumdar, founding CEO of Bicara Therapeutics, has been named as successor to Biocon founder Kiran Mazumdar-Shaw, with a gradual leadership transition planned.

She plans a gradual leadership transition over the next five years, with her niece Claire Mazumdar expected to assume the chair in a phased manner

Stocks to Watch today, April 8, 2026: Banks, Real estate, automobiles, Infosys, Aurobindo Pharma are some of the key stocks to watch today

According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were not known

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

Biocon Limited names Shreehas Tambe CEO, outlines AI-led, integration-driven strategy to boost global biosimilars and generics growth

Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .